Skip to Main Content

Paper Details

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
Ann Oncol
12
2021
Cancer, GEAs, KRAS, L1, MAPK, MSS, PATIENTS, PD-L1, Patients, RAS, TP53, TP53 mutations, Tumors, gastroesophageal adenocarcinoma, gastroesophageal adenocarcinomas, mismatch repair deficiency, mitogen-activated protein kinase, patient, patients, programmed death-ligand 1, tumor, tumors, women
Author NameAffiliation
Joanne Xiu
Joshua MillsteinNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
Matthew J Oberley
David Spetzler
  • 1 - 4

Datasets

Release 1.2